Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)

Oncogenic BRAF mutations have been widely described in melanomas and promote tumour progression and chemoresistance. We previously provided evidence that the HDAC inhibitor ITF2357 (Givinostat) targets oncogenic BRAF in SK-MEL-28 and A375 melanoma cells. Here, we show that oncogenic BRAF localises t...

Descripción completa

Detalles Bibliográficos
Autores principales: Celesia, Adriana, Franzò, Marzia, Di Liberto, Diana, Lauricella, Marianna, Carlisi, Daniela, D’Anneo, Antonella, Notaro, Antonietta, Allegra, Mario, Giuliano, Michela, Emanuele, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252263/
https://www.ncbi.nlm.nih.gov/pubmed/37298104
http://dx.doi.org/10.3390/ijms24119148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252263/
https://www.ncbi.nlm.nih.gov/pubmed/37298104
http://dx.doi.org/10.3390/ijms24119148

Ejemplares similares